louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05028491: The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients
Official title: The Effect of Meibomian Gland Thermal Massage on Corneal Aberrations in Meibomian Gland Dysfunction Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Meibomian Gland Dysfunction
Keywords: thermal massage
corneal aberrations
physical therapy
Lead sponsor: Wenzhou Medical University
Sponsor class: OTHER
First posted: 2021-08-31
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnosed as meibomian glands dysfunction in our hospital; treatment with thermal massage and expression

Brief summary: To evaluate the influence of corneal-aberrations before and after the meibomian gland thermal massage treatment.

Detailed description: 62 MGD patients treated with meibomian gland thermal massage once a week for 3 to 4 weeks were recruited.The Ocular Surface Disease Index questionnaire; tear film assessment encompassing tear meniscus height and non-invasive keratograph breakup time ; meibography score,corneal fluorescein staining; the Schirmer I test ; expressible meibomian gland, and quality ,anterior and total corneal aberrations were evaluated before and after treatment.

Eligibility criteria: Inclusion Criteria:

* tear break-up time (BUT) ≤10 seconds or Schirmer I test (SIT) ≤10 mm, the presence of dry eye symptoms, and fluorescein staining (FL) score \<3 points and at least one lid margin abnormality and poor meibomian gland expressibility

Exclusion Criteria:

* eyelid structure abnormal(Entropion , ectropion);
* having received any other treatment for MGD within three months
* history of ocular surgery
* contact lens use
* ocular infection
* any type of corneal scarring

Primary outcomes:
measure: corneal aberration corneal aberrations
timeFrame: baseline and 1 week after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Wenzhou
country: China
facility: Eye Hospital of Wenzhou Medical College
state: Zhejiang
Study officials:
affiliation: Ophthalmology and Optometry Hospital
name: Yune Zhao
role: STUDY_DIRECTOR
References:
Clinical trial NCT03876691: SHARE Model Communication Course and Do-not-resuscitate Signing
Official title: The Attendance to SHARE Model Communication Course by Physicians Increases the Signing of Do-not-resuscitate Orders for Critical Patients in the Emergency Room
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Trauma Injury
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2019-03-15
Enrollment: 145
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The research subjects consisted of attending physicians, who were willing to inform consent forms, in the emergency department between May 2017 and April 2018.

Brief summary: This study aimed to investigate the effect of attending a SHARE model communication course by emergency physicians on patient notification and signing of do-not-resuscitate (DNR) orders for critical patients in the emergency room.

Detailed description: An observation form designed based on the SHARE model was completed by two observers who noted the communication process between physicians and patients and family members during patient notification and signing a DNR order. To assess the influence of physicians attending a SHARE model course on the signing of DNR orders, a propensity score-matched population was created to reduce the potential selection bias of patients and family members.

Eligibility criteria: Inclusion Criteria:

* Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a "Do not resuscitate" order.
* Patients who was not register with "Do- not- resuscitate" on their health insurance card.

Exclusion Criteria:

* Trauma patients.
* Suicide patients.
* Patients of age less than 20.

Primary outcomes:
measure: Number of participants with DNR singing observation form
timeFrame: up to 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Chang Gung Memorial Hospital
Study officials:
affiliation: Chang Gung Memorial Hospital
name: TSANG-TANG Hsieh, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02739191: Negative Pressure Wound Therapy for Surgical Wounds of the Foot and Ankle
Official title: Negative Pressure Wound Therapy for Surgical Wounds of the Foot and Ankle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Negative Pressure Wound Therapy
Vacuum Therapy
Closed Incisions
Keywords: NPWT
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor class: OTHER
First posted: 2016-04-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Prophylactic use of Negative Pressure Wound Therapy (NPWT) on surgical wounds following lower extremity orthopedic trauma to prevent infectious complications.


Eligibility criteria: Inclusion Criteria:

* Patients ≥18 and ≤ 80 years
* Orthopedic (trauma) surgery to the foot and/or ankle
* Incision \>3 cm

Exclusion Criteria:

* Open fractures
* Antibiotic treatment at the time of the operation for a concomitant disease or infection
* Insufficient comprehension of the Dutch language
* Patients with immune-deficiencies
* Inability to address negative pressure wound therapy device
* Active infection

Primary outcomes:
measure: Number patients with postoperative wound infections (POWI) as classified bij the Centers for Disease Control and prevention (CDC)-criteria.
timeFrame: 30 days
Secondary outcomes:
measure: The American Orthopaedic Foot and Ankle Score (AOFAS) will be measured at six months
timeFrame: 6 months
measure: EuroQol five dimensions questionnaire (EQ-5D)will be measured at six months
timeFrame: 6 months
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Academic Medical Center
state: Noord-Holland
Study officials:
References:
Clinical trial NCT01389791: MgSO4 Combined With Rocuronium Priming
Official title: MgSO4 Combined With Rocuronium Priming
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Muscle Relaxation
Keywords: muscle relaxation
magnesium sulfate
rocuronium
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2011-07-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Priming with either rocuronium or MgSO4 is known to accelerate the effect of rocuronium on muscle relaxation. The purpose of this study is to define the effect of MgSO4 on the rocuronium-priming.

Detailed description: Acceleration of muscle relaxation is beneficial in rapid-sequence intubation. If MgSO4 combined with priming is efficient in accelerating muscle relaxation, it would be an interesting alternative to rapid-sequence intubation.

Eligibility criteria: Inclusion Criteria:

* patients of ASA Ⅰ-Ⅱ
* aged 18\~65
* scheduled to undergo elective surgery under general anesthesia

Exclusion Criteria:

* risk of pulmonary aspiration
* anticipated airway difficulty
* reactive airway disease
* allergic to study drugs
* neuromuscular / cardiovascular/ renal/ hepatic disease
* atrioventricular conduction disturbance
* BMI \< 18.5 or \> 24.9
* chronic treatment with calcium channel blocker
* medications which affect muscle relaxation

Primary outcomes:
measure: time from injection of induction dose of rocuronium until 95% depression of TOF
timeFrame: time from injection of induction dose of rocuronium until 95% depression of TOF, upto 5 min
Secondary outcomes:
measure: rocuronium duration
timeFrame: time from injection of induction dose of rocuronium until train-of-four count reaches two.
measure: intubating condition
timeFrame: time from injection of induction dose of rocuronium until tracheal intubation.
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul national university Bundang hospital
state: Kyoung-ki-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Sanghwan Do, M.D., PH.D.
role: STUDY_CHAIR
References:
Clinical trial NCT02728791: Comparison of Allows Measurement of Cardiac Output Between Clearsight System and Transpulmonary Thermodilution
Official title: Comparaison de Mesure de débit Cardiaque Entre système Clearsight® et Thermodilution Transpulmonaire.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Shock
Cardiac Output, Low
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2016-04-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults patients hospitalized in ICU with hemodynamic failure requiring vasoactive drugs

Brief summary: Correlation study between the data provided by two measurement systems, trans- pulmonary thermodilution and ClearSight © (non invasive), to determine the interest in routine use (cardiac output, cardiac index, stroke volume and blood pressure).

Detailed description: Since 2014, Edwards society has developed a completely non-invasive monitoring device for measurement of blood pressure and continuous cardiac output without inserting foreign intravascular bodies in the patient. Initially tested on healthy volunteers cardiac disease -free, the correlation with the other devices seems to be good. If this ClearSight © system show a relevant accuracy in measuring blood pressure and cardiac output with a specific ICU hospitalized population, it could justify its place in the therapeutic arsenal of monitoring in intensive care.

This is a common care ,prospective observational single center study , concerning the results of blood pressure , cardiac output values and their variations.

Eligibility criteria: Inclusion Criteria:

* age\>18
* hospitalized in surgical ICU, with hemodynamic instability or vaso-active drugs
* No opposition formulated

Exclusion Criteria:

* Impossibility of establishment of one of the cardiac output measurement devices
* Pregnant woman
* Refuse to participate

Primary outcomes:
measure: Comparison of values and changes in cardiac index between the two devices
timeFrame: 2 days
Secondary outcomes:
measure: Comparison of values and variations in mean arterial pressure between the two devices
timeFrame: 2 days
measure: Comparison of values and variations in mean cardiac output between the two devices
timeFrame: 2 days
measure: Comparison of values and variations in mean stroke volume variation between the two devices
timeFrame: 2 days
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU BREST, Hôpital de la Cavale Blanche
Study officials:
affiliation: CHRU de Brest
name: Olivier O HUET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03352791: The Dementia Symptom Management at Home Program Hospice Edition
Official title: A Cluster Randomized Controlled Trial (RCT) of the Dementia Symptom Management (DSM) at Home Program Hospice Edition
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Dementia
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2017-11-24
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Alzheimer's Disease and Related Disorders (dementia) poses a significant challenge to our public health. While many persons with dementia are cared for by friends and family in the community with the assistance of home healthcare and hospice, most clinicians and agencies are ill prepared to care for this population and therefore have difficulty assisting patients and caregivers in maintaining quality of life leading to adverse patient outcomes, increased caregiver stress and burnout, and healthcare utilization. This study will utilize a cluster randomized controlled design with 6 care teams at a single study site to examine the ability of a multi-component evidence-based practice hospice care quality improvement program for registered nurses, social workers and chaplains to improve the quality of life and reduce healthcare utilization for persons with dementia and their informal caregiver.


Eligibility criteria: Inclusion Criteria:

* PWD over the age of 65
* Admitted to MJHS hospice agency
* The patient and family caregiver speak English and/or Spanish.
* The informal caregiver is ≥18 years of age and spends at least 8 hours per week with the patient.
* Patients who score ≥6 on the Quick Dementia Rating Scale (at least mild impairment).

Exclusion Criteria:

* Patients with a separate Axis 1 diagnosis other than forms of dementia, depression or anxiety.
* PWD residing in assisted living facilities, nursing homes or board and care homes
* PWD solely receiving infusion or home health aide services.

Primary outcomes:
measure: Reduction in pain (PAINAD)
timeFrame: Day 0 and Day 30
measure: Reduction in Behavioral and Psychological Symptoms of Dementia (BPSD) using Neuropsychiatric Inventory Questionnaire (NPI-Q):
timeFrame: Day 0 and Day 30
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Abraham Brody, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01185691: Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients
Official title: RELIEF I: Investigating the Role of IMPELLA 2.5 System In Acutely Decompensated Chronic Heart Failure Patients. A Prospective, Single Center Feasibility Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Heart Failure
Lead sponsor: Abiomed Inc.
Sponsor class: INDUSTRY
Collaborators: name: McGill University Health Centre/Research Institute of the McGill University Health Centre
First posted: 2010-08-20
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to assess safety and feasibility of IMPELLA 2.5 in Acute Decompensated Heart Failure patients.


Eligibility criteria: Major Inclusion Criteria:

1. Chronic heart failure patients, hospitalized due to decompensated heart failure (ADHF) with NYHA Class III-IV symptoms (ADHF is defined by the presence of at least one of the following symptoms/signs: dyspnea w/orthopnea, jugular venous distension, peripheral edema +2, abdominal ascites, signs of CHF on chest X-Ray)
2. LVEF ≤ 40 % within the past 3 months

Major Exclusion Criteria:

1. Acute Q-wave myocardial infarction or Acute coronary syndrome within past 30 days
2. Cardiac surgery within the past 30 days
3. Implantation of cardiac resynchronization device within past 30 days or a possibility of implanting a biventricular pacer within 90 days of randomization

Primary outcomes:
measure: Major Adverse Events
timeFrame: 30 day or discharge(whichever is longer)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: McGill University Health Centre/Research Institute of the McGill University Health Centre
name: Renzo Cecere, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00579891: Tissue and Serum Collection From Colorectal Cancer Patients
Official title: Tissue and Serum Collection From Colorectal Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Cancer
Keywords: colorectal cancer
tissue collection
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2007-12-24
Enrollment: 726
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Colorectal cancer patients undergoing surgical resection

Brief summary: To establish a serum and tissue bank with specimens form patients with colorectal cancer, for subsequent immunological and biochemical analysis.


Eligibility criteria: Inclusion Criteria:

* Patients must be undergoing surgery for resection of their primary tumor, resection of hepatic metastases, or hepatic artery catheter and pump implant for unresectable hepatic metastases.
* For and tumor specimen removed at surgery ,the lesion must be large enough to allow for routine pathological analysis, with excision from residual otherwise discarded material for the tumor bank.

Exclusion Criteria:

N/A

Primary outcomes:
measure: establish a serum and tissue bank
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Philip Paty, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00803491: Health Related Quality of Life After a Self-promoting Learning Program for People With Rheumatic Diseases
Official title: Health Related Quality of Life After a Self-promoting Problem-based Learning Program for People With Rheumatic Diseases: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rheumatic Diseases
Keywords: Rheumatic diseases
Problem based learning
Health-related quality of life
Empowerment
Self-care
Lead sponsor: Spenshult Hospital
Sponsor class: OTHER
Collaborators: name: The Swedish Rheumatism Ass
name: County Council of Halland, Sweden
First posted: 2008-12-05
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Randomized controlled trial including 200 subjects with rheumatic diseases. Subjects will be randomized to either a self-promoting problem based learning (PBL) program or a control group with traditional care. The hypothesis is that a PBL program will improve health-related quality of life, empowerment and self-care ability.


Eligibility criteria: Inclusion Criteria:

* Subjects should have one or several rheumatic diseases diagnosed more than a year.
* Subjects should have musculoskeletal pain, sleep disturbances and fatigue, overwhelming number of days during the last three months.
* Subjects should be registered on the waiting list to the rheumatologic clinic.

Exclusion Criteria:

* Subjects with difficulties speaking and/or read Swedish.
* Subjects with difficulties travelling to the clinic.

Primary outcomes:
measure: Health related quality of life as measured by SF-36
timeFrame: Baseline, after intervention and six, twelve and thirtysix months after
Secondary outcomes:
measure: Empowerment as measured by ASES-S
timeFrame: Baseline, after intervention and six, twelve and thirtysix months after
measure: Empowerment measured by SWE-RES-23.
timeFrame: Baseline, after intervention and six, twelve and thirtysix months after
measure: Self-care ability measured by ASA-A.
timeFrame: Baseline, after intervention and six, twelve and thirtysix months after
measure: Sense of coherence (SOC).
timeFrame: Baseline, after intervention and six, twelve and thirtysix months after
Other outcomes:
Locations:
city: Oskarström
country: Sweden
facility: Spenshult Hospital
Study officials:
affiliation: R&D-centre Spenshult
name: Susann Arvidsson, PhD-student
role: PRINCIPAL_INVESTIGATOR
affiliation: R&D-centre Spenshult
name: Stefan Bergman, MD, PhD
role: STUDY_DIRECTOR
affiliation: R&D-centre Spenshult
name: Barbro Arvidsson, Professor
role: STUDY_CHAIR
affiliation: University of Jönköping, Sweden
name: Bengt Fridlund, Professor
role: STUDY_CHAIR
affiliation: University of Linköping
name: Pia Tingström, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00728091: A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
Official title: A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Hyponatremia
Inappropriate ADH Syndrome
Keywords: aquaretic
SIADH
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-08-05
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH.

Secondary objectives are to assess the safety of satavaptan, the maintenance of effect, and the clinical benefit in these participants.


Eligibility criteria: Inclusion Criteria:

* Participants with symptomatic syndrome of inappropriate antidiuretic hormone secretion (SIADH) with chronic hyponatremia

Exclusion Criteria:

* Presence of clinical signs of hypovolemia (e.g. orthostatic decreases in blood pressure and increase in pulse rate, dry mucus membranes, decreased skin turgor)
* Presence of clinical signs of hypervolemia (e.g. generalized edema, jugular venous extension)
* Participants with adrenocortical insufficiency
* Participants with hypothyroidism
* Participants with known causes of transient SIADH
* Participants with psychogenic polydipsia or beer potomania
* Concomitant use of thiazide diuretics during the study
* Presence of uncontrolled diabetes with fasting blood glucose ≥200 mg/dL (≥11.09 mmol/L) at time of screening
* Participants with impaired hepatic function or liver cirrhosis (Child-Pugh A-C)
* Pregnant or breast-feeding women

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Primary outcomes:
measure: serum sodium change from baseline
timeFrame: At Day 5 pre-dose
Secondary outcomes:
measure: responder rate
timeFrame: At Day 5 pre-dose
measure: presence and intensity of clinical symptoms related to hyponatremia
timeFrame: At each scheduled visit
measure: change from baseline in cognitive function
timeFrame: At Day 5 and 30
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Sanofi-Aventis Administrative Office
state: New Jersey
Study officials:
affiliation: Sanofi
name: ICD CSD
role: STUDY_DIRECTOR
References: